Form 4: Ikena Oncology CEO Reports Stock Transaction

Sentiment:

Insider Transaction (Form 4)


Kristin Yarema, Chief Executive Officer and a Director of Ikena Oncology, Inc., reported multiple transactions in common stock on July 25, 2026.

Summary

  • Option exercise/conversion: acquired 38,376 Common Stock on July 25, 2026; holds 123,776 after (Direct).
  • Other acquisition/disposition: acquired 115,129 Common Stock on July 25, 2026; holds 238,905 after (Direct).
  • Option exercise/conversion: disposed of 38,376 Restricted Stock Units on July 25, 2026; holds 115,129 after (Direct).
  • Other acquisition/disposition: disposed of 115,129 Restricted Stock Units on July 25, 2026 (Direct).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.

Insider Transactions

Kristin Yarema — Director, Officer (Chief Executive Officer)

DateTransactionSecuritySharesPriceValueHeld After
2026-07-25Option exercise/conversionCommon Stock38,376——123,776
2026-07-25Other acquisition/dispositionCommon Stock115,129——238,905
2026-07-25Option exercise/conversionRestricted Stock Units38,376——115,129
2026-07-25Other acquisition/dispositionRestricted Stock Units115,129——0

Key Dates

DateDescription
2026-07-25Option exercise/conversion (38,376 shares)
2026-07-25Other acquisition/disposition (115,129 shares)
2026-07-25Option exercise/conversion (38,376 shares)
2026-07-25Other acquisition/disposition (115,129 shares)

Keywords

insider transaction, Form 4, IMA, ImageneBio, Inc., neutral, Kristin Yarema

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.